MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma

Böni, R.; Doguoglu, A.; Burg, Günter; Müller, Beatrix; Dummer, Reinhard

doi:10.1016/s0190-9622(96)90607-6

Cited by 64 publications

(42 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some studies have shown an independent positive correlation between Ki-67 staining and metastatic potential and mortality in thick melanomas only; others have shown a similar correlation in thin melanomas only! 57,62,[67][68][69] Many studies have shown an increase in recurrence rate and mortality that directly correlates with increasing positivity for Ki-67; however, others have shown that this correlation is not independent of Breslow thickness. 60,61,63,[69][70][71][72][73] Reddy et al 74 did not find any correlation at all, although they only studied 14 cases.…”

Section: Markers Of Tumor Cell Proliferationmentioning

confidence: 99%

Immunohistochemical characteristics of melanoma

et al. 2008

View full text Add to dashboard Cite

Melanoma has a wide spectrum of histologic features which mimic epithelial, hematologic, mesenchymal, and neural tumors. Immunohistochemistry has been the primary tool to distinguish melanomas from these other tumors; it has also been studied for use as an adjunct to distinguish benign and malignant melanocytic tumors and to elucidate prognosis. Furthermore, there has been extensive effort to find a suitable marker to differentiate spindle cell and desmoplastic melanoma from other tumors. We have reviewed the literature investigating melanocytic differentiation markers, proliferation markers, immunomodulatory markers, signaling molecules, and nerve growth factors and receptors. Despite the proliferation of immunohistochemical markers, S‐100 remains the most sensitive marker for melanocytic lesions, while markers such as HMB‐45, MART‐1/Melan‐A, tyrosinase, and MITF demonstrate relatively good specificity but not as good sensitivity as S‐100. No marker has proven useful in distinguishing spindle cell and desmoplastic melanomas from other tumors. Ki67 remains the most useful adjunct in distinguishing benign from malignant melanocytic tumors. None of the markers reviewed has been shown conclusively to have prognostic value for melanocytic neoplasms.

show abstract

Section: Markers Of Tumor Cell Proliferationmentioning

confidence: 99%

Immunohistochemical characteristics of melanoma

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Increased proliferation and p53 immunopositivity have been shown to correlate with higher recurrence rates and reduced survival in certain cancers, and there is some evidence that these indices are associated with more advanced melanoma, and may help predict the subsequent development of metastases from this tumour (Bouzubar et al, 1989;Stretch et al, 1991;Quinlan et al, 1992;Sun et al, 1992;Allred et al, 1993;Furihata et al, 1993;Ishida et al, 1993;Florenes et al, 1994;Maeda et al, 1994;Ramsay et al, 1995;Boni et al, 1996). In addition, there is recent con¯icting evidence that altered regulation of p21 WAF1 protein (also known as melanoma di erentiation associated-6 (mda-6)), a downstream e ector of p53, occurs in more invasive melanomas (Jiang and Fisher, 1993;Jiang et al, 1995;Vidal et al, 1995;Wang and Becker, 1996).…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of allelic losses in primary melanoma

et al. 1998

View full text Add to dashboard Cite

Loss of genetic material, including loss of loci on chromosome arms 6q, 9p, and 10q, occurs frequently in cutaneous melanoma but infrequently in benign melanocytic nevi or other melanocytic lesions, suggesting that these genetic alterations are important in the development and progression of melanoma. To examine whether allelic loss is of prognostic importance in melanoma, disease-free survival was related to loss of heterozygosity on 6q, 9p and 10q in 83 individuals with sporadic primary cutaneous melanoma. Loss of chromosome arms 6q and 10q were each signi®cantly associated with a poorer clinical outcome (P=0.013 and P=0.001 respectively). In a subgroup of 41 subjects whose primary tumours were allelotyped, the fractional allelic loss (FAL) at 39 autosomal arms also signi®cantly correlated with disease-free survival (P=0.013), with an increase in FAL associated with a poorer outcome; this association remained signi®cant when controlled for tumour thickness (P=0.035). In addition, a greater proportion of cells were immunopositive for Ki67 antigen, p53 and p21 WAF1 protein in the primary melanomas than in the benign melanocytic nevi, however, only p53 overexpression was signi®cantly associated with improved survival (P=0.041).

show abstract

“…There is ample evidence that the size of the MM germinative compartment is indicative of the neoplastic progression (6,8,(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). A landmark study was performed 25 years ago using incorporations of tritiated thymidine (17).…”

Section: Growth Fraction In Melanocytic Neoplasmsmentioning

confidence: 99%

“…These findings were confirmed by other observations identifying the proliferation marker Ki-67 which is a nuclear antigen expressed in all active phases of the cell cycle of proliferation (G 1 , S, G 2 and M), but absent in the resting phase (G 0 ). Ki-67 immunolabeling was positive in <5% of nevocytes in most melanocytic nevi, but it commonly increased up to 15% in melanocytomas and it reached 15-30% or more in MM (3,7,13,14,20,23). Accordingly, there are two main clinical applications for using proliferation markers in this field, namely for distinguishing melanocytic nevi from MM, and for estimating the clinical prognosis in MM patients (10,(23)(24)(25)(26).…”

Section: Growth Fraction In Melanocytic Neoplasmsmentioning

confidence: 99%

Molecular pathways supporting the proliferation staging of malignant melanoma (Review)

2009

View full text Add to dashboard Cite

Abstract. The clinical diagnosis of cutaneous melanoma always calls for histological confirmation. In addition to the recognition of the classic aspects of the neoplasm, immunohistochemistry is determinant, in particular in the assessment of the size of the replicative compartment. Generally, the proliferation rate is indicative of the neoplastic progression and is related to the clinical growth rate of the neoplasm. It allows to distinguish high risk melanomas showing a high growth rate from those of lower malignancy associated with a restricted growth rate. In melanoma, the recruitment and progression of neoplastic cells in the cell cycle of proliferation have lost some of their controls that are normally processed by a series of key regulatory molecules. In addition, the apoptotic pathway counteracting any hyperproliferative activity is released of the dependency of specific regulated molecular mechanisms. This review summarizes the current knowledge on key molecular components involved in the deregulation of the growth fraction, cell proliferation and apoptosis in melanocytic neoplasms. The implication of cyclins and of the mitogen-activated protein kinase pathways are scrutinized. The involvement of neoplastic stem cells in the metastatic process is also discussed.

show abstract

MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma

Cited by 64 publications

References 8 publications

Immunohistochemical characteristics of melanoma

Immunohistochemical characteristics of melanoma

Prognostic significance of allelic losses in primary melanoma

Molecular pathways supporting the proliferation staging of malignant melanoma (Review)

Contact Info

Product

Resources

About